Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To study the properties of different tablets/capsules of AZD1305 in healthy male volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A: 2x2 crossover | Experimental | 4 different AZD1305 ER formulations |
|
| Part B: 3x3 crossover | Experimental | 2 different AZD1305 ER formulations and a reference formulation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD1305 | Drug | Extended release capsules, oral single doses |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetic variables | During all dosing visits |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events, ECG, safety laboratory, vital signs, physical examination | During the study |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Helen Lunde, MD | AstraZeneca R&D, Mölndal, Sweden | Study Director |
| Daniel Bradford, MD, MA, MBBS, DCPSA | PAREXEL Clinical Pharmacology Research UnitHarrow, United Kingdom | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Harrow | United Kingdom |
Not provided
| ID | Term |
|---|---|
| C550721 | tert-butyl (2-(7-(2-(4-cyano-2-fluorophenoxy)ethyl)-9-oxa-3,7-diazabicyclo(3.3.1)non3-yl)ethyl)carbamate |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AZD1305 |
| Drug |
Extended release capsules, oral single doses |
|